Most Recent
A long-awaited congressional report has called for an overhaul of medical device regulation in Australia, in the wake of a system-wide failure to protect women who suffered "devastating" consequences after being implanted with faulty vaginal mesh products.
Biogen said Thursday it will pull its multiple sclerosis drug Zinbryta in Australia, nearly two weeks after the biotech company issued a worldwide withdrawal of the drug following reports of encephalitus in Europe.
As Shine Lawyers awaits judgment in a marathon class action against Johnson & Johnson over its pelvic mesh implants, a separate class action by the firm kicked into gear Wednesday when a judge gave the ok to serve court papers on US-based American Medical Systems.
GlaxoSmithKline and Novartis have made another admission in a case brought by the ACCC alleging the drug giants made misleading claims in marketing their Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
Reckitt Benckiser has filed an appeal against GlaxoSmithKline, after a judge found the consumer goods giant misled consumers with claims that Nurofen was a more effective pain killer than its rival’s Panadol and ordered it to pay all of GlaxoSmithKline’s legal bill.
Pharmaceutical companies AstraZeneca and Generic Health have laid down their swords in a long-running patent dispute over AstraZeneca's cholesterol drug Crestor, two-and-a-half years after the High Court of Australia found the patent obvious and invalid.
Reckitt Benckiser has been ordered to pay all of GlaxoSmithKline's legal bill after a judge found the drug giant misled consumers with claims that Nurofen was a more effective pain killer than its rival's Panadol.
IP Australia handed a win Thursday to a company challenging a Bayer animal drug patent, but gave Bayer an additional two months to address its concerns about the patent application's deficiencies.
The Australian Patent Office has shot down a patent application covering throat lozenges by consumer goods giant Reckitt-Benckiser on a challenge by rival Sanofi-Aventis.
Drug giants GlaxoSmithKline and Novartis have conceded part of the ACCC's case that packaging on their Voltaren Osteo Gel breached the Australian Consumer Law, but said the label was changed almost a year ago.